Malignant pleural mesothelioma (MPM) is a rare type of cancer with a grim prognosis. So far. no targetable oncogenic mutation was identified in MPM and biomarkers with predictive value toward drug sensitivity or resistance are also lacking. Nintedanib (BIBF1120) is a small-molecule tyrosine kinase inhibitor that showed promising efficacy preclinically and in phase II trial in MPM as a... https://www.roneverhart.com/100-Percent-Sunglasses-SPEEDCRAFT-LE-Money-Mike-HiPER-Silver-Mirror/